Dark

Check out our Level2View

OGEN
Oragenics Inc.
stock NYSEAMERICAN

Nov 6, 2025

1.12USD-2.193%(-0.02)46,728

Pre-market

0.00USD0.000%(0.00)0

After-hours

0.00USD0.000%(0.00)0

OverviewHistoricalExchangesShortsNews

Jan 26, 2022

07:37AM EST Oragenics Announces Adjournment Of Annual Meeting Of Shareholders Due To Lack Of Quorum RTTNews

Jan 10, 2022

03:44PM EST US Health & Human Services Says, Starting Jan. 15, 2022, Individuals With Private Health Insurance/Group Health Plan Who Buy Over-The-Counter COVID Tests Will Have Costs Covered By Plan/Insurance Benzinga

Jan 4, 2022

12:17PM EST Mid-Day Market Update: Nasdaq Dips 250 Points; TherapeuticsMD Shares Surge Benzinga

Jan 3, 2022

04:35PM EST Oragenics Shares Spike Higher; Co Reports In Form 4 Filing Director Robert Koski Buys 1M Shares At Average Price Of $0.47/Share Benzinga

Dec 20, 2021

08:13AM EST Oragenics Extends Collaboration With National Research Council Of Canada To Develop Vaccine Against Omicron Variant RTTNews

08:07AM EST Oragenics Extends Collaboration With The National Research Council Of Canada To Develop Vaccine Against The Omicron Variant Benzinga

Dec 9, 2021

08:00AM EST Oragenics to Participate in Virtual Fireside Chat Hosted by Alliance Global Partners Business Wire

Dec 8, 2021

08:00AM EST Oragenics Co-Authors a Publication Describing the Dual Mechanism of Action of Lantibiotics Business Wire

Dec 1, 2021

08:08AM EST Oragenics Announces Positive COVID-19 Study Results Evaluating Multiple Formulations Of SARS-CoV-2 Vaccine Candidate RTTNews

08:04AM EST Oragenics Reports COVID-19 Challenge Study Results Evaluating Multiple Formulations Of Its SARS-CoV-2 Vaccine Candidate: 'Both formulations [in hamster model] generated robust immune responses and reduced the SARS-CoV-2 viral loads' Benzinga

08:00AM EST Oragenics Announces Positive COVID-19 Challenge Study Results Evaluating Multiple Formulations of its SARS-CoV-2 Vaccine Candidate Business Wire

Nov 23, 2021

08:37AM EST Oragenics Announces Adjournment Of Annual Meeting Of Shareholders Due To Lack of Quorum Benzinga

Oct 26, 2021

06:03AM EDT The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 05.45 A.M. EDT). RTTNews

Oct 4, 2021

07:39AM EDT Oragenics Awarded A $250,000 Grant From The National Institute Of General Medical Sciences For The Continued Research And Development Of Lantibiotics Benzinga

07:34AM EDT Oragenics Awarded $250,000 Grant From NIGMS For The Continued Research And Development Of Lantibiotics RTTNews

07:30AM EDT Oragenics Awarded a $250,000 Grant from the National Institute of General Medical Sciences (NIGMS) for the Continued Research and Development of Lantibiotics. Business Wire

Sep 24, 2021

04:32PM EDT UPDATE: Oragenics Says Will Focus On Continuing Independent Research, Development Efforts Relative To Lantibiotics In Order To Identify New Compounds To Pursue Benzinga

04:31PM EDT Oragenics Says On Sept. 22, Co, Eleszto Genetika, Mutually Terminated Lantibiotic ECC Agreement Dated Mar. 1, 2021, Says Will Cease Pre-Clinical Development Of It's Product Candidate OG716, Other Compounds Covered By Lantibiotic ECC Benzinga

Sep 15, 2021

11:01AM EDT Oragenics Launches Animal Study For COVID-19 Vaccine Candidate Benzinga

07:34AM EDT Oragenics Initiates COVID-19 Challenge Study Evaluating Multiple Formulations Of SARS-CoV-2 Vaccine Candidate RTTNews

07:30AM EDT Oragenics Initiates COVID-19 Challenge Study Evaluating Multiple Formulations Of Its SARS-CoV-2 Vaccine Candidate Benzinga

Aug 30, 2021

07:34AM EDT Oragenics Announces The Stabilized Pre-Fusion Spike Protein Trimer Produced By Its Canadian Collaborator And Licensed By The Company From The National Institutes Of Health Generates Neutralizing Antibodies In Mice After Immunization Against SARS-CoV-2 Benzinga

07:30AM EDT Oragenics' SARS-CoV-2 Spike Protein Produces Neutralizing Antibodies in Mice with Intramuscular and Intranasal Adjuvants Business Wire

Aug 24, 2021

07:33AM EDT Oragenics Announces Postponement Of Annual Meeting Of Shareholders Due To Lack Of Quorum RTTNews

07:30AM EDT Oragenics Announces Postponement of Annual Meeting of Shareholders Business Wire

Jul 27, 2021

02:33PM EDT Mid-Afternoon Market Update: Nasdaq Tumbles 240 Points; Oragenics Shares Spike Higher Benzinga

12:28PM EDT Mid-Day Market Update: GasLog Partners Drops After Q2 Results; EyeGate Pharmaceuticals Shares Jump Benzinga

11:13AM EDT The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts Benzinga

11:13AM EDT Oragenics Enters Licensing Agreement With National Research Council Of Canada To Pursue Development Of SARS-CoV-2 Vaccines Benzinga

Jul 1, 2021

07:01AM EDT Oragenics Announces Adjournment of Annual Meeting of Shareholders Due to Lack of Quorum Business Wire

May 18, 2021

09:33AM EDT Oragenics Believes Existing Cash And Cash Equivalents will Fund Operating Plan Into Q3 Of 2022 RTTNews

07:39AM EDT Oragenics Issues Letter To Shareholders Benzinga

May 3, 2021

07:37AM EDT Alan Joslyn Resigns As CEO, President And Director Of Oragenics To Pursue Other Opportunities RTTNews

07:30AM EDT Oragenics Announce Changes in Management and Board of Directors Business Wire

Apr 14, 2021

10:31AM EDT OGEN: COVID-19 Vaccine Candidate Exhibits Protective Immunity in Benzinga

Mar 9, 2021

12:10PM EST Oragenics' COVID-19 Related Deal Pushes The Stock Higher Benzinga

09:16AM EST Oragenics Enters into Material Transfer Agreement With Biodextris For The Use Of Mucosal Adjuvant In Its Intranasal COVID-19 Vaccine; Financial Details Not Disclosed Benzinga

07:12AM EST Oragenics Enters Material Transfer Agreement With Biodextris For Mucosal Adjuvant For Intranasal COVID-19 Vaccine RTTNews

07:00AM EST Oragenics Enters into Material Transfer Agreement with Biodextris for Mucosal Adjuvant for Intranasal COVID-19 Vaccine Business Wire

Mar 8, 2021

08:45AM EST Oragenics to Participate in Two Investment Conferences During March Business Wire

Feb 12, 2021

08:00AM EST Oragenics Announces Recent Capital Raise and Warrant Exercises Totaling $21.9 Million and the Redemption of Its Series C Preferred Stock Business Wire

Feb 2, 2021

08:04AM EST Oragenics Announces Spike Protein Cov-2 S-2P Created By The NIH And Licensed By The Company Demonstrates Protective Immunity In Immunized Mice Challenged With Mouse-adapted Sars-CoV-2 Virus Benzinga

08:01AM EST SARS-CoV-2 Spike Protein Licensed by Oragenics from the NIH Demonstrates Protective Immunity in Mice Business Wire

Jan 14, 2021

07:16AM EST Oragenics Says Optimistic That Terra CoV-2 Vaccine Will Ultimately Prove To Have Several Advantages RTTNews

07:05AM EST Oragenics Issues Letter To Stockholders Benzinga

Jan 7, 2021

03:14PM EST Mid-Afternoon Market Update: Dow Rises 250 Points; 3D Systems Shares Spike Higher Benzinga

07:30AM EST Oragenics, Inc. (OGEN) has entered into a material transfer agreement with Adjuvance Technologies Inc. for use of the adjuvant TQL1055 in the company's Terra CoV-2 vaccine against COVID-19. The agreement calls for TQL1055 to be used in pre-clinical animal studies. RTTNews

07:18AM EST Oragenics Enters Into Material Transfer Agreement With Adjuvance Technologies For Use Of Adjuvant TQL1055 RTTNews

07:03AM EST Oragenics Enters Into Material Transfer Agreement With Adjuvance Technologies For COVID-19 Vaccine Adjuvant Benzinga

Dec 29, 2020

04:00PM EST Oragenics Announces Closing of $6.5 Million Registered Direct Offering Business Wire

Dec 24, 2020

08:32AM EST Oragenics, Inc. Announces $6.5M Registered Direct Offering Benzinga

08:30AM EST Oragenics, Inc. Announces $6.5 Million Registered Direct Offering Business Wire

Nov 24, 2020

11:37AM EST Oragenics Announces Closing of $6.0 Million Underwritten Public Offering Business Wire

Nov 20, 2020

02:33PM EST Mid-Afternoon Market Update: Dow Drops Over 100 Points; Mesoblast Shares Spike Higher Benzinga

12:37PM EST Mid-Day Market Update: Nasdaq Edges Higher; Nano Dimension Shares Plunge Benzinga

08:32AM EST Oragenics Prices $5.25M Offering Of 14.189M Shares At $0.37/Share Benzinga

08:30AM EST Oragenics Prices $5.25 Million Common Stock Offering Business Wire

Nov 19, 2020

05:14PM EST CORRECTING AND REPLACING Oragenics Announces Proposed Underwritten Public Offering Business Wire

04:23PM EST Organics Announces Proposed Underwritten Public Offering; No Terms Disclosed Benzinga

04:22PM EST Organics Announces Proposed Underwritten Public Offering Business Wire

Oct 6, 2020

10:35AM EDT Why Oragenics Stock Is Trading Higher Today Benzinga

08:11AM EDT Benzinga Pro's Top 5 Stocks To Watch For Tuesday, Oct. 6, 2020: DPZ, AZYO, OGEN, ALKS, AN Benzinga

07:31AM EDT FDA Broadly Supports Oragenics' Pre-IND Development Program for its SARS-CoV-2 Vaccine; Re-Affirms Plan to File IND Application by the End of 1Q21, Begin Phase 1 Study in Early 2Q21 Benzinga

07:30AM EDT FDA Broadly Supports Oragenics' Pre-IND Development Program for its SARS-CoV-2 Vaccine Business Wire

Sep 28, 2020

08:06AM EDT Oragenics Provides An Update On Funding For Its SARS-CoV-2 Vaccine RTTNews

07:32AM EDT Oragenics Says Has Been Informed Of BARDA's Determination Not To Enter Negotiation With Co.; Says 'a combination of factors, including availability of funds, precluded the agency from entering into negotiations at this time.' Benzinga

07:30AM EDT Oragenics Provides an Update on Funding for its SARS-CoV-2 Vaccine Business Wire

07:30AM EDT Oragenics Shares Halted News Pending Benzinga

Sep 11, 2020

07:30AM EDT Oragenics Inc. to Present at the H.C. Wainwright 22nd Annual Global Virtual Investment Conference Business Wire

Aug 20, 2020

08:37AM EDT Oragenics Signs Process Development and Manufacturing Agreement With Avid Bioservices for Coronavirus Vaccine Benzinga

08:33AM EDT Oragenics And Avid Bioservices Enter Process Development And drug Substance Manufacturing Agreement RTTNews

08:30AM EDT Oragenics Signs Process Development and Manufacturing Agreement With Avid Bioservices for Coronavirus Vaccine Business Wire

Jul 22, 2020

07:52AM EDT Oragenics Inc. (OGEN) said that the National Institutes of Health created stabilized pre-fusion spike protein (CoV-2 S-2P) licensed by the company has generated neutralizing antibodies in mice during immunization against SARS-CoV-2, the virus that causes COVID-19. RTTNews

07:38AM EDT Oragenics: Study Shows SARS-CoV-2 Spike Protein Licensed By Company From NIH Produces Neutralizing Antibodies RTTNews

07:35AM EDT Oragenics Says Preclinical Study Shows SARS-CoV-2 Spike Protein Licensed By Co. From NIH Produces Neutralizing Antibodies Benzinga

07:30AM EDT Preclinical Study Shows SARS-CoV-2 Spike Protein Licensed by Oragenics from the NIH Produces Neutralizing Antibodies Business Wire

Jul 14, 2020

05:11AM EDT 80 Biggest Movers From Yesterday Benzinga

Share